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Abstract
Background:  The major cause of primary hypothyroidism is autoimmune mediated with
progressive and permanent destruction of the thyroid gland resulting in life-long replacement
therapy. Treatable and reversible hypothyroidism is unusual and here forth is such a case due to
infection of the thyroid gland with Tropheryma whippleii, Whipple disease.
Case presentation: A 45 year-old female presented with symptoms and signs consistent with
primary hypothyroidism, which was also confirmed biochemically. Her response to thyroxine
replacement therapy was poor however, requiring a significantly elevated amount. Further
investigation revealed the presence of Whipple's disease involving the gastrointestinal trace and
possibly the thyroid gland. Her thyroxine requirement decreased drastically following appropriate
antimicrobial therapy for Whipple's disease to the extent that it was ceased. Thyrotropin releasing
hormone testing in the steady state suggested there was diminished thyroid reserve due to
Whipple's disease.
Conclusion: This is the first ante-mortem case report studying the possible involvement of the
thyroid gland by Whipple's disease. Despite the normalization of her thyroid function test
biochemically after antibiotic therapy, there is diminished thyroid reserve thus requiring close and
regular monitoring.
Background
A 45-year-old female presents with a 6-month history of
progressive tiredness, lethargy and mild, intermittent alo-
pecia. She also reported mild shortness of breath and
ankle swelling. Her family has noted a slowed mentation
with approximately 8 kg weight loss (~10% of body
weight) during this time. There was no fever, diarrhea,
abdominal pain, malaise or arthralgia on systemic review.
She has never smoked and there was no significant past
history. No first-degree relative had any history of thyroid
disease.
Case presentation
Clinically she appeared tired and lethargic and myxede-
matous looking with a body mass index of 28 kg/m2
(height of 1.58 m and weight 71 kg). She was oriented,
coherent and afebrile. Her vital signs were stable. There
was small and non-tender goiter and her general examina-
tion was normal. There was no generalized lymphadenop-
athy. Thyroid ultrasound showed a mildly enlarged gland
with volume of 12 mls (reference range (RR), 6–10)[1],
without any nodule. A 24-hour radioactive iodine showed
heterogenous patchy uptake and distribution at 15% (RR:
10–36). Her laboratory investigations are listed in Table 1.
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Levo-thyroxine was initiated but with very little improve-
ment in her symptoms despite assured compliance. At 6
weeks' review, her thyrotropin (TSH) remained at 75 mU/
L on 100 µg of L-thyroxine daily. The dose was adjusted
according to clinical symptoms and TSH values every 6–8
weeks. The latter was 66 mU/L on 200 µg of L-thyroxine,
52 mU/L on 300 µg and 58 mU/L on 400 µg daily. Finally,
she was maintained on 500 µg daily with steady state TSH
of 24.5 mU/L despite moderate improvement in symp-
toms only. Malabsorption then became evident given her
biochemical parameters (Table 1) and the 1 mg-thyroxine
absorption test confirmed such suspicion. Her fT4 con-
centrations rose modestly. Levels were 5.6, 7.8 and 8.1
pmol/L at 0, 2 and 4 hours respectively. Her anti-trans-
glutaminase antibody was normal, ruling out Coeliac's
disease. As her symptoms persisted, an upper gastrointes-
tinal endoscopy was performed which revealed, surpris-
ingly, a normal duodenal mucosal appearance.
Unfortunately, enteroscopic photography was not availa-
ble.
Diagnostic procedures for Whipple's disease (WD)
Histology of the biopsy the second part of the duodenum
revealed the typical appearance of WD including clubbed
epithelial villi and foamy macrophages, which were dia-
stase Periodic acid-Schiff (PAS) positive, infiltrating the
lamina propia (Figures 1 &2). Immunohistochemistry
was not available. WD was further confirmed by electron
microscopy (EM), (Figure 3), and positive polymerase
chain reaction (PCR) for TW in both duodenal tissue and
peripheral circulating leucocytes. Culture for atypical
mycobacterium from the biopsied tissue, as part of a neg-
ative control, was negative. PCR was done using specific
primers W3AF and W4AR established previously by Ram-
zan et al. [2]. Negative controls included normal duode-
nal tissue (PAS negative) from 2 patients and DNA from
Histology of the same biopsy at high-power magnification  using PAS stain, showing foamy macrophages containing the  characteristic rod-shaped inclusion bodies (arrow) Figure 2
Histology of the same biopsy at high-power magnification 
using PAS stain, showing foamy macrophages containing the 
characteristic rod-shaped inclusion bodies (arrow).
Table 1: Laboratory Parameters. (Numbers in parentheses 
represent the reference ranges.)
Haemoglobin (115–165 g/L) 94
White cell count (4.0–11.0 × 109 per L) 12.3
Platelet count (150–400 × 109 per L) 578
Erythrocyte Sedimentation Rate (<10 mm/hr) 38
Sodium(137–143 mmol/L) 138
Potassium (3.5–5.5 mmol/L) 3.4
Urea (3.6–6.8 mmol/L) 3.1
Creatinine (0.06–0.10 mmol/L) 0.05
Glucose (random) (3.0–7.7 mmol/L) 3.2
Calcium (2.18–2.50 mmol/L) 2.11
Ionised Calcium (1.04–1.24 mmol/L) 0.95
Phosphate (0.86–1.36 mmol/L) 0.88
CK (<120 U/L) 110
Total Cholesterol (<4.0 mmol/L) 3.9
Triglyceride (<1.8 mmol/L) 1.5
Iron (10–27 umol/L) 5
Ferritin (30–260 ug/L) 19
Transferrin (2.0–3.8 g/L) 8.4
Total iron binding capacity (48–68 umol/L) 77
Albumin (35–42 g/L) 28
Total protein (67–79 g/L) 55
TSH (0.4–4.0 mU/L) 88.4
Free tetra-iodothyronine (10.5–26.5 pmol/L) 4.3
Anti-thyroglobulin antibody titre (<1:100) <1:100
Anti-thyroperoxidase antibody titre (<1:100) <1:100
TSH Stimulating Immunoglobulin (<10 U/mL) < 10
Histology of the duodenal biopsy showing clubbed epithelial  villi with inflammatory infiltrate including numerous foamy  macrophages (haemtoxylin-eosin stain, magnification × 250) Figure 1
Histology of the duodenal biopsy showing clubbed epithelial 
villi with inflammatory infiltrate including numerous foamy 
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E. Coli. The result yielded a specific amplicon, 160 base
pair in size, analysed by agarose gel electrophoresis,
stained with ethidium bromide and visualized under UV
light. Both strands of the PCR product demonstrated
sequence homology with the TW 16S ribosomal RNA
gene sequences deposited in GenBank and EMBL data-
bases by means of the University of Wisconsin Genetic
Computer Group software package (Madison, Wiscon-
sin).
Two attempts at thyroid cytology aspirations were per-
formed to identify the presence of TW. Unfortunately,
both failed to extract adequate DNA to perform the iden-
tification of 16S rDNA by PCR amplification and sequenc-
ing. Cytological examination showed the presence of
cellular inflammatory infiltrates including a small
number of lymphocytes, which were PAS-negative.
Progress
The patient was diagnosed with WD and treated with Tri-
methoprim-Sulphamethoxazole (Bactrim) during which
she improved steadily and regained in reasonable health
in the following 6 months. She was able to return to work
as an assistant librarian, albeit part-time. A formal neuro-
logical assessment was not performed including cerebral
magnetic resonance imaging and cerebral spinal fluid
examination.
She then developed tremor and palpitation and her TSH
was found to be suppressed mandating thyroxine cessa-
tion. The patient remained off thyroxine and follow-ups
at 6 and 12 months showed a TSH of 2.6, 1.5 mU/L with
fT4 of 15.8 and 20.5 pmol/L respectively.
At the end of 12 months of antibiotic therapy, all her labo-
ratory parameters improved. She regained ~5 kg although
the patient was conscious of not regaining too much weight.
At that time, her TSH and fT4 levels were 3.2 mU/L and 19.5
pmol/L respectively. Her TSH levels in response to various
thyroxine doses are illustrated in Figure 4. Her thyroid auto-
antibodies status was unchanged. Her repeat PCR on
peripheral blood was negative for TW. At 18 months, as
there were concerns regarding thyroid reserve and despite
the normalization of her thyroid parameters, an intrave-
nous Thyrotropin Releasing Hormone (TRH) stimulation
test was performed. TSH levels rose from 1.8 to 89.8 and
65.0 mU/L at 0, 30 and 60 minutes respectively.
Long term follow-up included close monitoring of her
thyroid status. A repeat of her TRH stimulation test was
performed at 36 months was near identical to previous.
No repeat endoscopy and small bowel biopsy were per-
formed as clinical progress was satisfactory.
WD was historically considered a primarily gastrointesti-
nal disease with diarrhoea being the predominant symp-
tom. However, it is now widely accepted as a generalized
systemic disease involving many organs. The case report is
atypical in that patient concerned is female with few gas-
trointestinal symptoms [3,4]. The diagnostic procedures
available for the diagnosis of WD include small bowel
biopsy (SBB), EM findings and PCR. The appearance of
the SBB and relevant stainings are non-specific [5]. EM,
which some considered diagnostic, is time consuming
and is not routinely available. Similarly, PCR is useful but
is technically challenging. To further confound the issue,
TW detection using PCR has been found in salivary con-
tent of healthy subjects from England [6], sewage treat-
ment plants [7] and gastric juice and duodenum of
patients with no clinical signs or suspicion of WD [8].
Thus these three tools are non-specific on their own but a
combination of any two positive results can contribute to
the diagnosis [5]. Immunohistochemistry, staining for the
PAS containing granules in the bacteria, is pivotal in the
diagnosis. Cross-reaction is very low (with Shigella and
Streptococcus agalactiae) and thus is very useful [9]. How-
ever, this test is highly specialized, not readily and rou-
tinely available due to the rarity of the disease and hence
could not be performed. Recently, culture of the organism
has become possible but with great difficulties due to the
organism's slow growth with the calculated doubling time
of 18 days. Therefore this great advance remains mostly in
the research setting [5,10]. Where possible, culture for
organisms that can mimic the histological findings of
WD, such as Mycobacterium tuberculosis, should be car-
ried out as the results will heavily influence the choice of
antimicrobial therapy [4]. Thus, due to restricted availa-
bility of diagnostic tests, the diagnosis relies heavily on
the combination of clinical symptoms and signs, response
Electron microscope of the duodenum tissue, demonstrating  the typical appearance of TW organism Figure 3
Electron microscope of the duodenum tissue, demonstrating 
the typical appearance of TW organism. The bacteria 
(arrows) appear rod-shaped and consisted of a thick cell wall 
and granular-fibrillar cytoplasm.BMC Endocrine Disorders 2006, 6:3 http://www.biomedcentral.com/1472-6823/6/3
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to empirical and appropriate antibiotic and relevant
investigations where available.
The first alert to the malabsorption was the failure to nor-
malize TSH despite an incremental increase in thyroxine
dosage to above 1.6 µg/kg/day [11], the general dose
required dose to achieve euthyroidism. Additionally, the
biochemical parameters were suggestive of the condition
and this was further supported by the failure of serum thy-
roxine to rise following the 1 mg-thyroxine absorption
test. The low serum protein including albumin and pre-
sumably transthyretin (pre-albumin) would avail less
binding sites for the absorbed thyroxine and thus a rela-
tively higher level of free (active) thyroxine to exert its
effect upon peripheral tissues. Thus, this may have mod-
erated the degree of hypothyroidism symptomatically. A
trial of lio-thyronine (synthetic tri-iodothyronine) would
have provided additional evidence of malabsorption. The
lowering of TSH concentration at considerably higher
doses of thyroxine suggested there was some absorption,
probably from the large bowel [12]. However, as most of
the thyroxine is absorbed from the ileum, this is consist-
ent with the fact that WD commonly involves all portion
of the small bowel and rarely the colon. This was the pri-
mary reason for the lack of response to thyroxine supple-
ment.
It is highly probable that the WD putatively involved the
thyroid as evident by the concomitant presence of
hypothyroidism, the absence of thyroid auto-immunity
and the recovery of normal thyroid function following
antibiotic therapy, albeit with reduced thyroid reserve (see
below). Further evidence stems from the fact that TW has
been detected in many extra-intestinal organs ranging
from cardiac valves, synovium, lung and pituitary [13-16]
resulting in the corresponding clinical symptoms. In addi-
tion, the thyroid volume was slighted increased [1], sug-
gesting the presence of oedema and inflammation. The
thyroid nuclear uptake scan was inconclusive however.
The seeding of the thyroid with TW is likely to be haemo-
togenous in nature given the TW PCR positivity in circu-
lating mononuclear cells (MNC). Evidence of antibiotic
effectiveness was also evident by the clearance of TW from
circulating MNC and presumably thyroid tissue. It is
The relationship between TSH and thyroxine dosage during the course of treatment with oral antibiotic Figure 4
The relationship between TSH and thyroxine dosage during the course of treatment with oral antibiotic. The shaded area rep-
resents the TSH reference range.
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appreciated however that the correlation between sys-
temic Whipple's disease and its PCR positivity is far from
perfect and the use of MNC PCR to monitor response to
therapy remains controversial at this stage [15,17]. It is
also critical that the diagnosis of TW-induced hypothy-
roidism was one of exclusion after other causes of
hypothyroidism have been adequately excluded including
negative/normal thyroid autoantibody studies including
TSI. Ord's disease can cause transient hypothyroidism in
the presence of negative anti-TPO and anti-Tg but the
duration of hypothyroidism was probably too long for
this to be the case. Also, the autoantibody titres men-
tioned remained unchanged overtime.
The gold standard for a reassessment of the condition
would be a re-examination of the small bowel tissue for
the clearance of the organism and resumption of normal
bowel architecture. The patient, not unreasonably how-
ever, declined a repeat endoscopy due to a marked
improvement in clinical response to antibiotic. It should
be noted that WD and its characteristic PAS-positive gran-
ules on biopsy can remain positive for years after the treat-
ment has been completed [15]. Presumably then
duodenal tissue PCR for TW also remains positive for the
same reasons, illustrating the discrepancy between clinical
and histopathologic response. It remains to be seen if
these two entities represent an unviable or simply dor-
mant organism.
Although TW has been reported to involve the central
nervous system in up to 90% of cases at postmortem
examination [18], no such assessment was considered in
this case due to the absence of neurological signs and
excellent clinical progress. Agreeably, a proportion of WD
involving the CNS will go undiagnosed [19].
Although the infection plausibly involved the thyroid,
destruction must have been incomplete for euthyroidism
to return. There might have been oedema and partial
damage, impairing thyroid follicular function but with
enough residual tissue to recover to euthyroidism. Previ-
ous postmortem report found complete obliteration of
the thyroid gland with fibrous tissues [20]. There were foci
of lymphocytes and cells containing PAS granules, which
were not detected albeit in the FNA sample in this report.
Contrary to intestinal villi from the gastrointestinal tract,
which could be readily regenerated, thyroid tissues are not
and thus it is assumed that some, but not all thyroid tis-
sues are destroyed by the infective process. This is consist-
ent with a previous case report [16] in which there was
permanent panhypopituitarism despite the clearance of
TW (as performed by PCR) after 4 weeks of appropriate
antibiotic. Unfortunately and despite repeated attempts,
direct evidence of TW involving the thyroid could not be
obtained either by direct culture or PCR.
In order to assess thyroid reserve at the end of therapy, the
TRH stimulation test was performed and revealed an exag-
gerated TSH response indicating impaired thyroid reserve
[21,22]. This test was performed 18 months after the ini-
tial diagnosis of primary hypothyroidism to ensure that
thyrotrophic cells have recovered from hyperplasia that
can persist for weeks to months in primary hypothy-
roidism, even in the face of subsequent short-lived exoge-
nous thyrotoxicosis. Thyrotrophic hyperplasia needed to
be excluded because this can cause an augmented TRH-
stimulated response in hypothyroidism and therefore
may not reflect the patient's true thyroid status. In the
absence of any other factors that may impair thyroid
reserve, including smoking, iodine depletion and subclin-
ical autoimmune thyroiditis, the demonstrated and
diminished thyroid reserve can be attributed to TW infec-
tion. The patient is, of course, at risk of rapid and progres-
sive hypothyroidism when the abovementioned risk
factors intervened and hence requires frequent monitor-
ing. As the TRH tests are unchanged and her TSH levels
have remained normal so far, it can be deduced with con-
fidence that the destructive inflammatory process incited
by the presence of TW has been arrested but the damage
permanent with a reduced thyroid reserve.
Conclusion
The case highlights thyroid involvement by TW, causing
significant thyroid failure. Despite the evidence of TW
present in the duodenum and circulating leucocytes, its
presence in thyroid tissue could not only be indirectly
proven. However, the successful reversibility of the pri-
mary hypothyroidism in response to long-term anti-biotic
therapy indicates strongly that WD indeed involves the
thyroid gland in the absence of alternative causes. The
damage to the thyroid has also resulted in permanent and
reduced thyroid reserve as demonstrated by repeated TRH
stimulation tests but with normal thyrotropin levels. This
is only the second report that convincingly describes the
putative link between primary hypothyroidism and WD
and the first in a live patient with excellent recovery.
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